Last reviewed 2026-04-20 · How we verify

Endocaine (PYRROCAINE)

Phase 2 active Small molecule

Endocaine (generic name: PYRROCAINE) is a pyrrocaine drug. It is currently in Phase 2 development.

Endocaine works by blocking sodium channels in the nervous system.

Endocaine, also known as Pyrrocaine, is a small molecule drug in the pyrrocaine class. Its exact target and mechanism of action are unknown, but it is believed to work by blocking sodium channels in the nervous system. Endocaine is not FDA-approved for any indications, and its commercial status, including patent and generic availability, is unclear. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to fully understand Endocaine's properties and potential uses.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PYRROCAINE
Drug class	pyrrocaine
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your nerves are like electrical wires. Sodium channels are like the switches that control the flow of electricity. When Endocaine blocks these switches, it can help reduce pain by limiting the electrical signals that are sent to the brain.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Endocaine CI brief — competitive landscape report
Endocaine updates RSS · CI watch RSS

Frequently asked questions about Endocaine

What is Endocaine?

Endocaine (PYRROCAINE) is a pyrrocaine drug.

How does Endocaine work?

Endocaine works by blocking sodium channels in the nervous system.

What is the generic name of Endocaine?

PYRROCAINE is the generic (nonproprietary) name of Endocaine.

What drug class is Endocaine in?

Endocaine belongs to the pyrrocaine class. See all pyrrocaine drugs at /class/pyrrocaine.

What development phase is Endocaine in?

Endocaine is in Phase 2.

Drug class: All pyrrocaine drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing